Best Life Sciences Companies in Kfar Saba, Israel

VVT Medical has developed a medical technology for the treatment of varicose veins. Its procedure called V-Block includes a percutaneous delivery of vascular embolic device (called v-block device) into the proximal great saphenous vein (GSV) and induce a concomitant liquid sclerotherapy using its proprietary dual procedure syringe system by the simultaneous aspiration of the blood and the discharging of the sclerosing agent. Claims that the procedure requires no anesthesia and requires minimal post procedure care.

Manufacturer of endovascular suture-like device for cardiovascular treatment. It uses a smart stapling mechanism that enables multiple staples to simultaneously penetrate the stent graft and the aortic wall. With a small profile delivery system, the device, Aortoseal is quickly deployed via a single release action. It enables the implementation of endograft procedures in almost all types of anatomies and can dramatically reduce complications and reinterventions.

Funding rounds

• Jul 2024Series A$10M
• Feb 2023Grant (prize money)$2.7M
• 2022Grant (prize money)$2.8M
• Dec 2021Seed$5M

Founders & team

Ron KarmeliCo-Founder & CMO

Investors

Sofinnova Partners, EIC Fund, MD Start, MedTech Innovator

CathWorks is developing FFRAngio, a novel technology for angiogram-based physiology measurement that does not require pressure wires or hyperemic stimulus. It is based on the processing of visual information and automatic multi-layered algorithms. Its technology is focused on improving the utilization of coronary angiography data to validate measurement-based medicine in the cath lab.

Funding rounds

• Jul 2022Series E$75M
• Jan 2021Series D$30M
• Feb 2019Series C$30M
• Oct 2017Series B$15.8M

Founders & team

Ifat LaviFounder & CTO

Investors

Medtronic, Deerfield, Quark Venture, Planven Investments, Pontifax, Corundum Open Innovation

Tech stack

Animate.CssCloudflareCloudflare Bot ManagementComplianzCore-JsGodaddy

CartiHeal provides of implant for bone and cartilage regeneration. The company has developed a cell-free implant Agili-C that enables bone and cartilage regeneration in a single-step procedure. Agili-C is CE marked for the treatment of focal articular cartilage and osteochondral defects.

Funding rounds

• Jul 2020Series D$15M
• Jan 2018Series C$2.5M
• May 2017Series C$18.3M
• Jan 2016Series B$15M

Founders & team

Nir AltschulerCEO & Founder

Investors

Bioventus, aMoon, Johnson & Johnson Innovation – JJDC, Peregrine Ventures, Elron Ventures, Access Medical Ventures

Tech stack

Cart FunctionalityWordpressMysqlPhpYoast SeoNginx

Developer of non-invasive system for pulmonary congestion assessment and management. The system uses remote dielectric sensing for monitoring lung fluid levels. It is designed for patients with heart failure and other chronic diseases. The system measurement takes less than a minute and can be performed at the point of care.

Developer of an intraluminal bypass device designed to reduce the rate of diverting stomas and their related complications. The company's devices contain an alternative to divert stoma by providing a temporary intraluminal bypass which helps in reducing the contact of fecal materials with the anastomotic site, reducing the life-threatening symptoms related to clinical anastomotic leaks, enabling doctors to maintain patients' well-being in a safe and effective manner and minimizing post-operative complications for a comfortable recovery.

Funding rounds

• Jun 2022Grant (prize money)$2.4M
• Sep 2017Series A$8M
• Mar 2017Grant (prize money)$52.7K
• Jan 2017Grant (prize money)$52.1K

Founders & team

Boaz AssafCEO

Investors

Europa, Docor, AmiTechnion, Clal Biotechnology Industries, Triventures, EIC Fund

Enzymotec develops and produces biofunctional ingredients to address health needs associated with the human life cycle, starting from babies up to seniors. It develops, manufactures and markets bio-functional lipid ingredients, as well as final products, based on proprietary processes and technologies. Offerings encompass two segments - Nutrition ingredients for infant formulas and dietary supplements (sold through Advanced Lipids, our joint venture with AAK) and branded lipid-based medical foods for the dietary management of medical disorders and phospholipid-based bioactive ingredients for nutritional supplements. Other nutritional ingredients include krill oil and dietary supplements targeted at improving brain health providing benefits in memory, learning abilities and concentration. Enzymotec subsidiary Vaya Pharma manufactures lipid-based products for addressing dietary issues in Attention Deficit Hyperactivity Disorder (ADHD) and Hypertriglyceridemia.

MetaCure develops implantable devices for the treatment of Type 2 (adult) diabetes. Their key product, Diamond (Tantalus) is implanted under the abdominal skin in a one-time surgery. The small implanted DIAMOND device detects when eating begins, and automatically sends gentle pulse signals (gastric contractility modulation signals, or GCM) to the stomach muscles. As a result, the DIAMOND restores the physiological synchronization between food intake and natural hormone secretion, and lowers post meal glucose levels. Additionally, GCM signals cause an earlier satiation effect resulting in sustained weight loss. The external device is used to charge the implanted device wirelessly once a week by the patient at home. It can be used for up to 15 years before a replacement is needed.. As of July 2016, Diamond-I has received CE mark and is approved for sale in Europe, Australia and other international markets. It is not approved for use in the USA. Metacure's offices are located in Hamilton, New York, Stuttgart and Sydney. The company is backed by the Hobart Group.

Funding rounds

• Apr 2009Series B$20M

Founders & team

Mateusz ZelewskiCEOShlomo Ben-HaimChairman & Founder

Investors

Morningside, Hobart Group

NLT SPINE, specializes in the development and marketing of Minimally Invasive Spinal Surgery (MISS) products for treating degenerative spinal conditions. Their products are based on non-linear core technology that allows inserting large implants and instruments through a small incision. They have developed the product PROW FUSION for Transforaminal Lumbar Interbody Fusion (TLIF) is based on the application of non-linear technology.

Kyma Medical Technologies develops patient monitoring solutions to improve care of patients suffering from chronic cardiac illnesses. The company has developed a proprietary technology for the detection and monitoring of changes in fluid contents, based on a proprietary RF sensing technology. Kyma’s solutions aim at providing healthcare professionals with accurate information on the patient's clinical status for support of medical decision-making. Kyma’s technology is currently applied via external use, and a subcutaneous approach is under development, thus meeting the needs of a variety of patient populations. The Kyma µ-Cor is CE Mark-approved for monitoring of one or more of the following clinical parameters: Thoracic Fluid Content, ECG, heart rate, respiratory rate, activity and body posture. As of November 2016, the device is not FDA approved and still under investigation in the US.

Funding rounds

• Oct 2013Series A$10M

Founders & team

Uriel WeinsteinCo-founder

Investors

Ganot Capital, Rafael Development Corporation, Elron Ventures

Wrist-based Pulse Oximetry health monitor. It helps in remote patient monitoring using predictive and adaptive analytics. Its capabilities include detecting loss of pulse and unhealthy variations in other key vital signs, and automatically triggering an alert to emergency responders. It uses a proprietary algorithm for tracking blood oxygenation from wrist and was one of the finalists at Three Year Health Entrepreneurship Programme by GE and Startup Health in 2013.

Funding rounds

• Apr 2015Grant (prize money)$55.1K
• Nov 2014Grant (prize money)$62.6K
• Sep 2014Seed$3M

Founders & team

Leon EisenFounder & Executive Chairman

Investors

EIC Fund, TMC Innovation, Europa, Connecticut Innovations, Gefen Biomed Investments, StartUp Health

Tech stack

CloudflareCloudflare Bot ManagementContact Form 7Cookie NoticeFont AwesomeGodaddy

ReDent Nova, a medical technology company, develops dental devices and instruments. They have developed, Self-Adjusting File System, a minimally-invasive endodontic technology for 3D cleaning and shaping using a single instrument. The SAF edge System includes the EndoStation mini, an endodontic motor for Self-Adjusting Files as well as Rotary instruments.

Funding rounds

• Jul 2006Seed$2.7M
• Dec 2004Seed$500K

Founders & team

Zeev SchriberCEO

Investors

Infinity Group, Maayan Ventures, Partners500